KR840006198A - 항원성 합성 펩타이드의 제조방법 - Google Patents
항원성 합성 펩타이드의 제조방법 Download PDFInfo
- Publication number
- KR840006198A KR840006198A KR1019830003951A KR830003951A KR840006198A KR 840006198 A KR840006198 A KR 840006198A KR 1019830003951 A KR1019830003951 A KR 1019830003951A KR 830003951 A KR830003951 A KR 830003951A KR 840006198 A KR840006198 A KR 840006198A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- isoleucine
- asparagine
- glycine
- proline
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 16
- 238000000034 method Methods 0.000 title claims 4
- 230000000890 antigenic effect Effects 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 26
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 13
- 239000004471 Glycine Substances 0.000 claims 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 13
- 235000009582 asparagine Nutrition 0.000 claims 13
- 229960001230 asparagine Drugs 0.000 claims 13
- 229960002449 glycine Drugs 0.000 claims 13
- 235000014705 isoleucine Nutrition 0.000 claims 13
- 229960000310 isoleucine Drugs 0.000 claims 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- 235000013930 proline Nutrition 0.000 claims 8
- 229960002429 proline Drugs 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 7
- 239000004473 Threonine Substances 0.000 claims 7
- 235000009697 arginine Nutrition 0.000 claims 7
- 229960003121 arginine Drugs 0.000 claims 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 235000018977 lysine Nutrition 0.000 claims 7
- 229960003646 lysine Drugs 0.000 claims 7
- 235000008521 threonine Nutrition 0.000 claims 7
- 229960002898 threonine Drugs 0.000 claims 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 6
- 229920005990 polystyrene resin Polymers 0.000 claims 6
- 229920005989 resin Polymers 0.000 claims 6
- 239000011347 resin Substances 0.000 claims 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 5
- 235000004279 alanine Nutrition 0.000 claims 5
- 229960003767 alanine Drugs 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- 229960002433 cysteine Drugs 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 235000013922 glutamic acid Nutrition 0.000 claims 5
- 229960002989 glutamic acid Drugs 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 5
- 235000004554 glutamine Nutrition 0.000 claims 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 5
- 229960002743 glutamine Drugs 0.000 claims 5
- 235000008729 phenylalanine Nutrition 0.000 claims 5
- 229960005190 phenylalanine Drugs 0.000 claims 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- 229960005261 aspartic acid Drugs 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 235000004400 serine Nutrition 0.000 claims 4
- 229960001153 serine Drugs 0.000 claims 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000014304 histidine Nutrition 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 229960002885 histidine Drugs 0.000 claims 3
- 235000005772 leucine Nutrition 0.000 claims 3
- 229960003136 leucine Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000006109 methionine Nutrition 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 229960004452 methionine Drugs 0.000 claims 3
- 235000014393 valine Nutrition 0.000 claims 3
- 229960004295 valine Drugs 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960004799 tryptophan Drugs 0.000 claims 2
- 235000002374 tyrosine Nutrition 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 229960004441 tyrosine Drugs 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 뉴클레오타이드 서열로 부터 유도된 X-47HA 분자의 아미노산 서열을 나타내는 도20*.
제2도는 마딘-다비(Madin-Darby)개 신장(MDCK) 상피세포에 대한 X-47인플루엔자 바이러스의 미량 적정 결과를 나타낸는 도.
제3도는 항-펩타이드 향혈청의 조합에 대한 X-47 바이러스의 중화를 나타내는 도.
Claims (9)
- t-BOC-로이신 -폴리스티렌수지를 제조하여, 이수지에 차단된 형태의 이소로이신, 알기닌, 히스티딘, 프롤린, 아스파라긴, 아스파라긴 및 시스테인을 연속적으로 커플링시키고 생성된 수지로부터 다음 구조식(Ⅰ)의 펩타이드를 분리, 회수함을 특징으로하여, 구조식(Ⅰ)의 펩타이드를 제조하는 방법.CNNPHRIL (Ⅰ)
- t-BOC-티로신-폴리스티렌 수지를 제조하여, 이수지에 차단된 형태의 트레오닌, 이소로이신, 리신, 아스파라긴 발린, 아스파라긴, 글루타민, 페닐알라닌, 프롤린, 리신, 아스파르트산, 아스파라긴, 프롤린, 이소로이신, 세린, 글리신,아스파라긴, 프롤린, 트레오닌, 이소로이신, 시스테인, 글루탐산, 세린, 시스테인, 트레오닌, 글리신, 이소로이신, 프롤린, 알라닌, 아스파르트산, 세린, 알기닌, 메티오닌, 이소로이신 및 세린을 연속적으로 커플링시키고 생성된 수지로부터 다음 구조식(Ⅱ)의 펩타이드를 분리, 회수함을 특징으로하여, 구조식(Ⅱ)의 펩타이드를 제조하는 방법.SIMRSDAPIGTCSSECITPNGSIPNDKPFQNVNKITY (Ⅱ)
- t-BOC-시스테인-폴리스티렌 수지를 제조하여, 이수지에 차단된 형태의 아스파라긴, 글루타민, 히스티딘, 알기닌, 페닐알라닌, 글리신, 티로신, 트립토판, 글리신, 아스파르트산, 이소로이신, 메티오닌, 글리신, 글루탐산, 트립토판, 글리신. 아스파라긴, 글루탐산, 이소로이신, 페닐알라닌, 글리신, 알라닌, 이소로이신, 알라닌, 글리신, 페닐알라닌, 이소로이신, 글리신 및 알기닌을 연속적으로 커플링시키고 생성된 수지로 부터 다음 구조식(Ⅲ)의 펩타이드를 분리, 회수함을 특징으로하여, 구조식(Ⅲ)의 펩타이드를 제조하는 방법.RGIFGAIAGFIENGWEGMIDGWYGFRHQNC (Ⅲ)
- t-BOC-시스테인-폴리스티렌 수지를 제조하여, 이 수지에 차단된 형태의 알라닌, 그릴신, 페닐알라닌, 이소로이신, 글리신, 알기닌, 트레오닌, 글루타민, 리신 및 글루탐산을 연속적으로 커플링 시키고 생성된 수지로 부터 다음 구조식(Ⅳ)의 펩타이드를 분리, 회수함으로 특징으로 하여, 구조식(Ⅵ)의 펩타이드를 제조하는 방법.EKQTRGIFGAC (Ⅵ)
- t-BOC-알기닌-폴리스티렌 수지를 제조하여, 이 수지에 차단된 형태의 트레오닌, 글루타민, 리신,글루탐산, 프롤린, 발린, 아스파라긴, 알기닌, 메티오닌, 글리신, 트레오닌, 알라닌, 로이신, 리신, 로이신, 트레오닌, 아스파라긴, 글루타민, 리신, 발린, 티로신, 리신, 프롤린 및 시스테인을 연속적으로 커플링시키고 생성된 수지로 부터 다음 구조식 (Ⅴ)의 펩타이드를 분리, 회수함을 특징으로 하여 구조식(Ⅴ)의 펩타이드를 제조하는 방법.CPKYVKQNTLKLATGMRNVPEKQTR (Ⅴ)
- t-BOC-시스테인-폴리스티렌수지를 제조하여, 이수지에 차단된 형태의 아스파라긴, 이소로이신, 글리신, 아스파르트산, 로이신, 이소로이신, 알기닌, 히스티딘, 프롤린, 아스파라긴, 아스파라긴 및 시스테인을 연속하여 커플링시키고 생성된 수지로 부터 다음 구조식(Ⅵ)의 펩타이드를 분리, 회수함을 특징으로 하여 구조식(Ⅵ)의 펩타이드를 제조하는 방법.CNNPHRILDGINC (Ⅵ)
- 상기항에서 정의한 구조식(Ⅰ) 내지 (Ⅵ)의 항원적으로 활성인 합성 펩타이드를 제조하고, 이합성펩타이드를, 동물 호스트에게 주사하였을 때 인플루엔자에 대한 중화 항체를 유발시키시에 충분한 양으로 생리적으로 허용되는 액체 부형제에현탁시킴을 특징으로하여, 면역화 조성물을 제조하는 방법.
- 제7항에 있어서, 상기 펩타이드를 현탁 시키기전에 단백질 담체에 커플링시키는 방법.
- 제7항에 있어서, 상기 펩타이드를 현탁 시키기전에 단백질 담체에 커플링시키는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41045582A | 1982-08-23 | 1982-08-23 | |
| US410455 | 1999-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR840006198A true KR840006198A (ko) | 1984-11-22 |
Family
ID=23624803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019830003951A KR840006198A (ko) | 1982-08-23 | 1983-08-23 | 항원성 합성 펩타이드의 제조방법 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0116629A4 (ko) |
| JP (1) | JPS59501714A (ko) |
| KR (1) | KR840006198A (ko) |
| AU (1) | AU570929B2 (ko) |
| DK (1) | DK203684D0 (ko) |
| ES (1) | ES8505819A1 (ko) |
| FI (1) | FI841583A0 (ko) |
| GR (1) | GR78931B (ko) |
| IL (1) | IL69556A (ko) |
| IT (1) | IT1168636B (ko) |
| NO (1) | NO161002C (ko) |
| NZ (2) | NZ220612A (ko) |
| PH (1) | PH18872A (ko) |
| PT (1) | PT77230B (ko) |
| WO (1) | WO1984000687A1 (ko) |
| ZA (1) | ZA836080B (ko) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR241713A1 (es) * | 1984-08-30 | 1992-11-30 | Smithkline Beckman Corp | Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe. |
| US5866363A (en) | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| WO1990008161A1 (en) * | 1989-01-12 | 1990-07-26 | The Blood Center Of Southeastern Wisconsin | Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses |
| EP0621339B1 (en) * | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| JP2996864B2 (ja) * | 1994-03-30 | 2000-01-11 | 寳酒造株式会社 | 抗体可変領域ｄｎａ |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| WO2007134327A2 (en) * | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| EP2450377A1 (en) * | 2006-09-07 | 2012-05-09 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
| ITTO20070066A1 (it) | 2007-01-30 | 2008-07-31 | Pomona Biotechnologies Llc | Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv |
| WO2008118970A2 (en) | 2007-03-27 | 2008-10-02 | Sea Lane Biotechnologies, Llc | Constructs and libraries comprising antibody surrogate light chain sequences |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| CN102046656A (zh) | 2008-03-28 | 2011-05-04 | 航道生物技术有限责任公司 | 针对病毒抗原的中和性分子 |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| ITTO20080964A1 (it) | 2008-12-22 | 2010-06-23 | Natimab Therapeutics S R L | Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv |
| JP5780762B2 (ja) | 2008-12-25 | 2015-09-16 | 国立大学法人大阪大学 | 抗ヒトインフルエンザウイルス・ヒト型抗体 |
| JP2012521786A (ja) | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| CN102482345A (zh) * | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
| WO2010138564A1 (en) | 2009-05-26 | 2010-12-02 | Mount Sinai School Of Medicine Of New York University | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| IT1395961B1 (it) * | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
| KR20120132506A (ko) * | 2010-02-18 | 2012-12-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신 |
| WO2011123495A1 (en) | 2010-03-30 | 2011-10-06 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| CA2842860A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies, Llc | Sur-binding proteins |
| US10131695B2 (en) | 2011-09-20 | 2018-11-20 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| EP2793940B1 (en) | 2011-12-22 | 2018-11-14 | i2 Pharmaceuticals, Inc. | Surrogate binding proteins |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| CA2895508A1 (en) | 2012-12-18 | 2014-06-26 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| JP2018504412A (ja) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン接種レジメン |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| US11266734B2 (en) | 2016-06-15 | 2022-03-08 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI83662C (fi) * | 1980-07-17 | 1991-08-12 | Scripps Clinic Res | Diagnostik antikropp och foerfarande foer dess framstaellning. |
-
1983
- 1983-08-17 ZA ZA836080A patent/ZA836080B/xx unknown
- 1983-08-19 GR GR72254A patent/GR78931B/el unknown
- 1983-08-22 IT IT48868/83A patent/IT1168636B/it active
- 1983-08-22 NZ NZ220612A patent/NZ220612A/xx unknown
- 1983-08-22 NZ NZ205341A patent/NZ205341A/xx unknown
- 1983-08-22 PT PT77230A patent/PT77230B/pt unknown
- 1983-08-22 ES ES525088A patent/ES8505819A1/es not_active Expired
- 1983-08-23 KR KR1019830003951A patent/KR840006198A/ko not_active Application Discontinuation
- 1983-08-23 AU AU19471/83A patent/AU570929B2/en not_active Ceased
- 1983-08-23 EP EP19830902869 patent/EP0116629A4/en not_active Withdrawn
- 1983-08-23 IL IL69556A patent/IL69556A/xx unknown
- 1983-08-23 PH PH29428A patent/PH18872A/en unknown
- 1983-08-23 JP JP58502916A patent/JPS59501714A/ja active Pending
- 1983-08-23 WO PCT/US1983/001291 patent/WO1984000687A1/en not_active Application Discontinuation
-
1984
- 1984-04-17 NO NO841540A patent/NO161002C/no unknown
- 1984-04-18 DK DK2036/84A patent/DK203684D0/da not_active Application Discontinuation
- 1984-04-19 FI FI841583A patent/FI841583A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IT8348868A0 (it) | 1983-08-22 |
| PT77230A (en) | 1983-09-01 |
| ES525088A0 (es) | 1985-06-16 |
| IL69556A0 (en) | 1983-11-30 |
| NO161002C (no) | 1989-06-21 |
| FI841583A (fi) | 1984-04-19 |
| ZA836080B (en) | 1984-04-25 |
| ES8505819A1 (es) | 1985-06-16 |
| WO1984000687A1 (en) | 1984-03-01 |
| GR78931B (ko) | 1984-10-02 |
| PT77230B (en) | 1986-02-04 |
| PH18872A (en) | 1985-10-21 |
| AU1947183A (en) | 1984-03-07 |
| FI841583A0 (fi) | 1984-04-19 |
| DK203684A (da) | 1984-04-18 |
| IT1168636B (it) | 1987-05-20 |
| AU570929B2 (en) | 1988-03-31 |
| IL69556A (en) | 1988-05-31 |
| NZ205341A (en) | 1988-07-28 |
| NO841540L (no) | 1984-04-17 |
| EP0116629A1 (en) | 1984-08-29 |
| NZ220612A (en) | 1988-07-28 |
| JPS59501714A (ja) | 1984-10-11 |
| NO161002B (no) | 1989-03-13 |
| DK203684D0 (da) | 1984-04-18 |
| EP0116629A4 (en) | 1987-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR840006198A (ko) | 항원성 합성 펩타이드의 제조방법 | |
| du Vigneaud et al. | The Synthesis of Lysine-vasopressin1 | |
| Sanger | Fractionation of oxidized insulin | |
| Brew et al. | The complete amino acid sequence of bovine α-lactalbumin | |
| Porter | Chemical structure of γ-globulin and antibodies | |
| Weil et al. | Reaction of reduced disulfide bonds in α-lactalbumin and β-lactoglobulin with acrylonitrile | |
| Furthmayer et al. | Chemical properties of the peptide extension in the pα 1 chain of dermatosparactic skin procollagen | |
| BREW | The Complete Amino‐Acid Sequence of Guinea‐Pig α‐Lactalbumin | |
| Fujimaki et al. | Diffusable bitter peptides in peptic hydrolyzate of soybean protein | |
| Morino et al. | The Subunit Structure of Tryptophanase: II. A CORRELATION OF ULTRACENTRIFUGAL AND CHEMICAL STUDIES | |
| KR840005080A (ko) | 디노르핀 아미드 동족체의 제조방법 | |
| Rathnam et al. | Subunits of luteinizing hormone from human pituitary glands | |
| JPS56110617A (en) | Nutrient composition for young child | |
| Ressler et al. | The Isoglutamine Isomer of Oxytocin: Its Synthesis and Comparison with Oxytocin1 | |
| Brew et al. | The isolation and characterization of the tryptic, chymotryptic, peptic, and cyanogen bromide peptides from bovine α-lactalbumin | |
| Photaki | A New Synthesis of Oxytocin Using S-Acyl Cysteines as Intermediates1, 2 | |
| GB1394846A (en) | Polypeptides | |
| KR840005665A (ko) | 면역계에 작용하는 폴리펩티드의 분리 및 정제방법 | |
| Katsoyannis et al. | The synthesis of the histidine analog of the vasopressins | |
| King et al. | The chemistry of tyrocidine. V. The amino acid sequence of tyrocidine B | |
| Kornguth et al. | The Stability and Rearrangement of iε-N-Glutamyl-Lysines | |
| Kerckaert et al. | Electrophoretic preparation of the two rat a-fetoprotein variants | |
| Yamashiro et al. | Isomeric dimers of oxytocin | |
| Li et al. | The synthesis of L-histidyl-L-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and L-histidyl-D-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and their melanocyte-stimulating activity | |
| Jarvis et al. | The Synthesis of 1-(Hemi-homocystine)-oxytocin and A Study of Some of its Pharmacological Properties1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |